Moxonidine Effects on Neuropeptide Y

Aristotle University Of Thessaloniki90 enrolled

Overview

Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obesity Hypertension

Interventions

MoxonidineDRUG

0.6 mg moxonidine daily

Eligibility

Sex: ALLMin age: 25 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy Exclusion Criteria: * age beyond 25-75 years, * not taking currently anti-hypertensive medication * not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Outcomes

Primary Outcomes

serum Neuropeptide Y levels

ELISA

Time frame: 12 weeks

systolic blood pressure

mmHg

Time frame: 12 weeks

diastolic blood pressure

mmHg

Time frame: 12 weeks

Secondary Outcomes

Weight

Time frame: 12 weeks

Body Mass Index

kg/m2

Time frame: 12 weeks

Total Cholesterol

mg/dl

Time frame: 12 weeks

HDL Cholesterol

mg/dl

Time frame: 12 weeks

LDL Cholesterol

mg/dl

Time frame: 12 weeks

Serum triglycerides

mg/dl

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.